Villicana Patrick, Whiting Bryant, Goodison Steve, Rosser Charles J
Department of Urology, The University of Florida, College of Medicine, Suite N2-3, PO Box 100247, Gainesville, FL 32610, USA.
Biomark Med. 2009 Jun 1;3(3):265. doi: 10.2217/bmm.09.23.
Bladder cancer is one of the most prevalent cancers worldwide. Furthermore, nonmuscle invasive bladder cancer has a 70% rate of recurrence, making it a considerable strain to the healthcare system. Patients with bladder cancer require repeat cystoscopic examinations of the bladder to monitor for tumor recurrence. The reason these patients have to undergo these costly, painful, invasive procedures is owing to the absence of accurate urine-based assays to detect the presence of bladder cancer noninvasively. Consequently, the development of a urine-based test to detect bladder cancer would be of tremendous benefit to both patients and healthcare systems. This article reports some of the more prominent urine markers in use today. In addition, the article will highlight some new technologies that are used to investigate novel urinary markers.
膀胱癌是全球最常见的癌症之一。此外，非肌层浸润性膀胱癌的复发率为70%，给医疗系统带来了相当大的压力。膀胱癌患者需要定期进行膀胱镜检查以监测肿瘤复发。这些患者不得不接受这些昂贵、痛苦且有创的检查，原因是缺乏准确的基于尿液的检测方法来无创检测膀胱癌的存在。因此，开发一种基于尿液的膀胱癌检测方法将对患者和医疗系统都大有裨益。本文报道了目前一些较为突出的尿液标志物。此外，本文还将重点介绍用于研究新型尿液标志物的一些新技术。
